<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002035</url>
  </required_header>
  <id_info>
    <org_study_id>039B</org_study_id>
    <secondary_id>AI454-010</secondary_id>
    <nct_id>NCT00002035</nct_id>
  </id_info>
  <brief_title>Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine</brief_title>
  <official_title>Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of orally administered didanosine (ddI) with orally
      administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical
      deterioration despite treatment with AZT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 1992</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed for Hematologic toxicity:

          -  Erythropoietin.

          -  Colony-Stimulating Factors.

          -  Allowed for prophylaxis of Pneumocystis carinii pneumonia (PCP):

          -  Aerosolized pentamidine.

          -  Trimethoprim/sulfamethoxazole.

          -  Dapsone.

          -  NOTE:

          -  If intravenous pentamidine is required for treatment of PCP, study drug should be
             suspended until one week after completion of intravenous pentamidine.

          -  Allowed:

          -  Prophylactic or suppressive therapy begun prior to study entry with the exception of
             neurotoxic agents (as defined in the protocol).

        Concurrent Treatment:

        Allowed:

          -  Transfusions for hematologic toxicity.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Active acute AIDS defining infection.

          -  Clinical evidence of acute pancreatitis in the last two years or chronic pancreatitis.

          -  Dementia of such severity that patient cannot give informed consent.

          -  Grade 2 or worse peripheral neuropathy as defined by Targeted Neuropathy Score
             (Schaumberg).

          -  Prior Cytomegalovirus disease requiring ongoing systemic ganciclovir therapy.

          -  Extensive Kaposi's sarcoma or other malignancy requiring systemic cytotoxic
             myelosuppressive or neurotoxic chemotherapy.

          -  Cardiomyopathy or the need for antiarrhythmic therapy.

          -  Inability to tolerate at least 600 mg per day of zidovudine (AZT).

          -  Seizures within the last 6 months or the need for anticonvulsant therapy.

        Concurrent Medication:

        Excluded:

          -  Ganciclovir (DHPG).

          -  Myelosuppressive or neurotoxic chemotherapy.

          -  Antiarrhythmic therapy.

          -  Anticonvulsant therapy.

          -  Neurotoxic agents (as defined in the protocol).

          -  NOTE:

          -  If intravenous pentamidine is required for treatment of Pneumocystis carinii pneumonia
             (PCP), study drug should be suspended until 1 week after completion of intravenous
             pentamidine.

        Patients with the following are excluded:

          -  Symptoms and conditions defined in the Patient Exclusion Co-Existing Conditions field.

          -  Average of two sequential CD4 counts from SciCor Clinical Laboratories in the 30 days
             prior to study entry &gt; 300 cells/mm3.

        Prior Medication:

        Excluded, participation in studies using:

          -  Dideoxyinosine (ddI).

          -  2',3'-Dideoxy-2',3'-didehydrothymidine (d4T).

          -  Dideoxycytidine (ddC).

          -  Excluded within one month of study entry:

          -  Any other experimental antiretroviral compounds.

        Patients must:

          -  Have documented HIV positivity via ELISA.

          -  Meet CDC criteria for AIDS or AIDS related complex (ARC).

          -  Have received zidovudine (AZT) for = or &gt; 6 months and tolerated a dose of at least
             500 mg per day without significant hematologic toxicity.

          -  Have no acute AIDS defining opportunistic infection, but may be receiving suppressive
             therapy for such infections.

          -  Demonstrate at least one of the following criteria for clinical deterioration despite
             AZT therapy within 4 weeks prior to study entry (8 weeks prior for weight loss):

          -  involuntary weight loss of more than 5 percent of the body weight occurring over the 8
             week period prior to study entry, Karnofsky score = or &gt; 50 but demonstrating a fall =
             or &gt; 20 from previous level of functioning (assessment must be persistent on two
             occasions at least 14 days apart), unexplained fever of = or &gt; 38 degrees C (despite
             evaluation defined in protocol) for more than 7 days, appearance of newly diagnosed
             oral hairy leukoplakia or oral candidiasis, or recurrence of a previously quiescent
             multidermatomal varicella-zoster, appearance of dermatologic afflictions (e.g.
             psoriasis, molluscum contagiosum, or newly diagnosed seborrheic dermatitis),
             appearance of chronic herpetic ulcers not responsive to acyclovir therapy.

        Required:

          -  Zidovudine (AZT) for = or &gt; 6 months prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Arizona / Health Science Ctr</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Univ Med School</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G E Morey Jr</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VP Med Services / HHCS Research Institute Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Veterans Administration Hosp</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Kansas School of Medicine</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Med College / AIDS Treatment Ctr</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med College of Ohio</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania / HIV Clinic</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Southwestern Med Ctr of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>775550882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Audie L Murphy Veterans Administration Hosp</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stephen L Green</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milwaukee County Med Complex</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPR School of Medicine</name>
      <address>
        <city>San Juan</city>
        <zip>009275800</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>Ruedy N, et al. Results of long term follow-up of a double blind study of ddI vs continued AZT among individuals with CD4s 200-500/mm3. Int Conf AIDS. 1994 Aug 7-12;10(2):16 (abstract no 358B)</citation>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>AIDS-Related Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

